Office of Research
Clinical Trials

Leading the Future of Clinical Medicine
The College of Medicine is a hub for groundbreaking clinical research. With over 30 specialized research units, our teams are dedicated to translating laboratory discoveries into life-saving clinical applications. From neurology to oncology, we provide the infrastructure and expertise necessary to push the boundaries of modern medicine.

Browse our Research Units below to view current study listings.

Clinical Trials Search

E. Steve S. Woodle, MD

E. Steve S. Woodle, MD

Transplant

Monitoring Immune Responses After Kidney Transplant

This research study is focused on people who are receiving a kidney transplant. The goal is to learn more about how the body's immune system responds to a new kidney. By studying blood, urine, and small samples of kidney tissue that are already collected as part of routine care, researchers hope to better understand why some transplanted kidneys work well while others develop problems. People who join the study do not receive a new treatment, but their participation may help improve care for future kidney transplant patients.

E. Steve S. Woodle, MD

E. Steve S. Woodle, MD

Transplant

Immune profiling of kidney transplant rejection

Researchers are studying why kidney transplant rejection occurs by analyzing blood, urine, and kidney biopsy samples collected during standard clinical care. The goal is to better understand immune activity during rejection and support future improvements in transplant treatment. Participation does not involve experimental treatment.

E. Steve S. Woodle, MD

E. Steve S. Woodle, MD

Transplant | Surgery

Phase 1

AT1501 Kidney Transplant Study

This is a Phase 1b, open-label study that will test AT-1501 in up to 48 people receiving a first kidney transplant. AT-1501 is given with standard transplant medicines: rATG as induction, low-dose corticosteroids, and mycophenolate for maintenance. The study will track safety issues, measure how the drug behaves in the body (drug levels and related measures), and look for signs that it helps prevent rejection. Safety will be followed through the study (about up to 20 months on average). Pharmacokinetic sampling is planned soon after the first dose and again at steady state around Month 3. The study is single-arm, so every participant receives AT-1501 alongside routine transplant care.

Learn More about AT1501 Kidney Transplant Study
Amit Govil, MD

Amit Govil, MD

Transplant | CKD

Phase 2

Finerenone in Kidney Transplants

This study will test a medicine called finerenone in people who have had a kidney transplant. The trial will enroll 150 transplant recipients and will compare finerenone to a placebo in a double-blind, randomized design over about 13 months. The team will check whether it is possible to recruit transplant patients and whether they will accept extra tests like research kidney biopsies and special kidney MRIs. The study will also look at safety and tolerability, especially the risk of high potassium and changes in kidney function. Researchers will measure urine protein, kidney function over time, heart failure events needing care, changes seen on kidney MRI, and changes seen on biopsy tissue in the biopsy subgroup. Results will help decide if larger trials are needed.

Learn More about Finerenone in Kidney Transplants
E. Steve S. Woodle, MD

E. Steve S. Woodle, MD

Transplant

Blood sample collection from living kidney donors

Researchers are studying how cells from kidney donors interact with the recipient's immune system during transplant rejection. Living kidney donors may be asked to provide a one-time blood sample, which will be used in laboratory studies only. There is no treatment involved, and participation is voluntary. [PROTOCOL V...6_18_2018 | PDF]